Le Lézard
Classified in: Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024


Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2023 financial results and provide a business update on Thursday, March 7, 2024, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13743722. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Puretm technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolyssetm, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau®, Nuceiva®, and Evolyssetm are trademarks of Evolus, Inc.
Hi-Puretm is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.


These press releases may also interest you

at 02:17
Fun88 Announces Title Sponsorship of Vizag Warriors for the Andhra Premier League
Fun88, a leading company in sports and entertainment, proudly announces its official title sponsorship with the Vizag Warriors for the Andhra Premier League (APL)....

at 02:00
Azentio expands its leadership team with 2 new appointments
Azentio Software ("Azentio") - a leading end-to-end software company specializing in the BFSI sector, today announced the appointment of Aarthi Ramesh as Chief Customer Officer and Emma Foley as Chief Marketing Officer....

at 01:52
Invitation to presentation of EQT AB's Half-year Report 2024
EQT AB's Half-year Report 2024 will be published on Thursday 18 July 2024 at approximately 07:00 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session. The presentation and a video link for the webcast...

3 jui 2024
Metro Vancouver Properties Corp. announces completion of going private transaction
Metro Vancouver Properties Corp. ("Metro Vancouver"), a Vancouver-based real estate company announces that it has completed its previously announced going private transaction (the "Transaction") by way of a share consolidation. Under the share...

3 jui 2024
Gritstone bio, Inc. Sued for Securities Law Violations - Contact The Rosen Law Firm Before August 6, 2024 to Discuss Your Rights - GRTS
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. between March 9, 2023 and February 29, 2024, both dates inclusive (the "Class Period"), of the important August 6, 2024 lead plaintiff...

3 jui 2024
Advantex Announces Appointment of New Chief Financial Officer
Advantex Marketing International Inc. ("Advantex"), a leader in the merchant cash advance and loyalty marketing products for merchants, announced the appointment of Santhosh Kumar as its new Chief Financial Officer, effective June 24, 2024....

More news about Business...


News published on and distributed by: